The Beat AML Master Trial found high remission rates and promising safety with triplet therapy in patients with acute myeloid leukemia (AML), according to Ashley Yocum, PhD.

Moleculin Biotech gets US FDA positive feedback on paediatric study plan for Annamycin in children with R/R AML: Houston Saturday, June 21, 2025, 15:00 Hrs [IST] Moleculin Biotech ...

Scientists at St. Jude Children's Research Hospital and Dana-Farber Cancer Institute today report the identification of a ...

Scientists at St. Jude Children's Research Hospital and Dana-Farber Cancer Institute today report the identification of a novel combination therapy ...

Panelists explain that KMT2A-rearranged acute myeloid leukemia (AML) is a biologically aggressive and diagnostically complex leukemia subtype—especially prevalent in pediatric and therapy-related ...

Scientists at St. Jude Children's Research Hospital and Dana-Farber Cancer Institute today report the identification of a novel combination therapy approach to treat pediatric acute myeloid leukemia ...

At just 11 years old, Aurelia Awa of West Oʻahu has already overcome more challenges than most face in a lifetime. Diagnosed ...

Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer FDA recommends inclusion of patients as young as 6 months - younger than ...

Watch the “What This Means" segment here HOUSTON, June 18, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ( ...

Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer FDA recommends inclusion of patients as young as 6 months – younger than ...